| __timestamp | Bausch Health Companies Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 59644696 |
| Thursday, January 1, 2015 | 2682700000 | 79541000 |
| Friday, January 1, 2016 | 2810000000 | 98015000 |
| Sunday, January 1, 2017 | 2582000000 | 103958000 |
| Monday, January 1, 2018 | 2473000000 | 103654000 |
| Tuesday, January 1, 2019 | 2554000000 | 128951000 |
| Wednesday, January 1, 2020 | 2367000000 | 135799000 |
| Friday, January 1, 2021 | 2624000000 | 149883000 |
| Saturday, January 1, 2022 | 2625000000 | 220206000 |
| Sunday, January 1, 2023 | 2917000000 | 265542000 |
Cracking the code
In the competitive landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. Bausch Health Companies Inc. and Travere Therapeutics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Bausch Health, a major player, consistently reported higher SG&A costs, peaking at nearly $2.9 billion in 2023, reflecting a 44% increase from 2014. This trend underscores their expansive operations and market reach. In contrast, Travere Therapeutics, a smaller entity, saw its SG&A expenses grow by over 340% during the same period, reaching approximately $266 million in 2023. This surge highlights Travere's aggressive growth strategy and increasing market presence. These financial trajectories offer a window into each company's strategic priorities and operational scale, providing valuable insights for investors and industry analysts alike.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Bausch Health Companies Inc.
SG&A Efficiency Analysis: Comparing BeiGene, Ltd. and Bausch Health Companies Inc.
Insmed Incorporated or Bausch Health Companies Inc.: Who Manages SG&A Costs Better?
Ascendis Pharma A/S or Bausch Health Companies Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Jazz Pharmaceuticals plc and Travere Therapeutics, Inc.
Grifols, S.A. vs Bausch Health Companies Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Grifols, S.A. vs Travere Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Rhythm Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Bausch Health Companies Inc. or Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Dynavax Technologies Corporation and Travere Therapeutics, Inc.
Taro Pharmaceutical Industries Ltd. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?